A Phase II/III Study of JR-141 in Patients With Mucopolysaccharidosis II
Latest Information Update: 17 Mar 2022
At a glance
- Drugs Pabinafusp alfa (Primary)
- Indications Mucopolysaccharidosis II
- Focus Registrational; Therapeutic Use
- Sponsors JCR Pharmaceuticals
- 15 Feb 2022 Results published in the JCR Pharmaceuticals Media Release.
- 15 Feb 2022 According to a JCR Pharmaceuticals media release, data from this study was presented at 18th Annual WORLDSymposium.
- 23 Mar 2021 According to a JCR Pharmaceuticals media release, the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome). The approval is based on of evidence from non-clinical and clinical studies(including this and a phase II/III study).